<?xml version='1.0' encoding='utf-8'?>
<document id="17578901"><sentence text="Species difference in the inhibitory effect of nonsteroidal anti-inflammatory drugs on the uptake of methotrexate by human kidney slices."><entity charOffset="101-113" id="DDI-PubMed.17578901.s1.e0" text="methotrexate" /></sentence><sentence text="Simultaneous use of nonsteroidal anti-inflammatory drugs (NSAIDs), probenecid, and other drugs has been reported to delay the plasma elimination of methotrexate in patients"><entity charOffset="67-77" id="DDI-PubMed.17578901.s2.e0" text="probenecid" /><entity charOffset="148-160" id="DDI-PubMed.17578901.s2.e1" text="methotrexate" /><pair ddi="false" e1="DDI-PubMed.17578901.s2.e0" e2="DDI-PubMed.17578901.s2.e0" /><pair ddi="false" e1="DDI-PubMed.17578901.s2.e0" e2="DDI-PubMed.17578901.s2.e1" /></sentence><sentence text=" Previously, we have reported that inhibition of the uptake process cannot explain such drug-drug interactions using rats" /><sentence text=" The present study quantitatively evaluated the possible role of the transporters in such drug-drug interactions using human kidney slices and membrane vesicles expressing human ATP-binding cassette (ABC) transporters" /><sentence text=" The uptake of methotrexate by human kidney slices was saturable with a K(m) of 45 to 49 microM"><entity charOffset="15-27" id="DDI-PubMed.17578901.s5.e0" text="methotrexate" /></sentence><sentence text=" Saturable uptake of methotrexate by human kidney slices was markedly inhibited by p-aminohippurate and benzylpenicillin, but only weakly by 5-methyltetrahydrofolate"><entity charOffset="21-33" id="DDI-PubMed.17578901.s6.e0" text="methotrexate" /><entity charOffset="83-99" id="DDI-PubMed.17578901.s6.e1" text="p-aminohippurate" /><entity charOffset="104-120" id="DDI-PubMed.17578901.s6.e2" text="benzylpenicillin" /><entity charOffset="141-165" id="DDI-PubMed.17578901.s6.e3" text="5-methyltetrahydrofolate" /><pair ddi="false" e1="DDI-PubMed.17578901.s6.e0" e2="DDI-PubMed.17578901.s6.e0" /><pair ddi="false" e1="DDI-PubMed.17578901.s6.e0" e2="DDI-PubMed.17578901.s6.e1" /><pair ddi="false" e1="DDI-PubMed.17578901.s6.e0" e2="DDI-PubMed.17578901.s6.e2" /><pair ddi="false" e1="DDI-PubMed.17578901.s6.e0" e2="DDI-PubMed.17578901.s6.e3" /><pair ddi="false" e1="DDI-PubMed.17578901.s6.e1" e2="DDI-PubMed.17578901.s6.e1" /><pair ddi="false" e1="DDI-PubMed.17578901.s6.e1" e2="DDI-PubMed.17578901.s6.e2" /><pair ddi="false" e1="DDI-PubMed.17578901.s6.e1" e2="DDI-PubMed.17578901.s6.e3" /><pair ddi="false" e1="DDI-PubMed.17578901.s6.e2" e2="DDI-PubMed.17578901.s6.e2" /><pair ddi="false" e1="DDI-PubMed.17578901.s6.e2" e2="DDI-PubMed.17578901.s6.e3" /></sentence><sentence text=" These transport characteristics are similar to those of a basolateral organic anion transporter (OAT) 3/SLC22A8" /><sentence text=" NSAIDs and probenecid inhibited the uptake of methotrexate by human kidney slices, and, in particular, salicylate, indomethacin, phenylbutazone, and probenecid were predicted to exhibit significant inhibition at clinically observed plasma concentrations"><entity charOffset="47-59" id="DDI-PubMed.17578901.s8.e0" text="methotrexate" /><entity charOffset="104-114" id="DDI-PubMed.17578901.s8.e1" text="salicylate" /><entity charOffset="116-128" id="DDI-PubMed.17578901.s8.e2" text="indomethacin" /><entity charOffset="130-144" id="DDI-PubMed.17578901.s8.e3" text="phenylbutazone" /><entity charOffset="150-160" id="DDI-PubMed.17578901.s8.e4" text="probenecid" /><pair ddi="false" e1="DDI-PubMed.17578901.s8.e0" e2="DDI-PubMed.17578901.s8.e0" /><pair ddi="false" e1="DDI-PubMed.17578901.s8.e0" e2="DDI-PubMed.17578901.s8.e1" /><pair ddi="false" e1="DDI-PubMed.17578901.s8.e0" e2="DDI-PubMed.17578901.s8.e2" /><pair ddi="false" e1="DDI-PubMed.17578901.s8.e0" e2="DDI-PubMed.17578901.s8.e3" /><pair ddi="false" e1="DDI-PubMed.17578901.s8.e0" e2="DDI-PubMed.17578901.s8.e4" /><pair ddi="false" e1="DDI-PubMed.17578901.s8.e1" e2="DDI-PubMed.17578901.s8.e1" /><pair ddi="false" e1="DDI-PubMed.17578901.s8.e1" e2="DDI-PubMed.17578901.s8.e2" /><pair ddi="false" e1="DDI-PubMed.17578901.s8.e1" e2="DDI-PubMed.17578901.s8.e3" /><pair ddi="false" e1="DDI-PubMed.17578901.s8.e1" e2="DDI-PubMed.17578901.s8.e4" /><pair ddi="false" e1="DDI-PubMed.17578901.s8.e2" e2="DDI-PubMed.17578901.s8.e2" /><pair ddi="false" e1="DDI-PubMed.17578901.s8.e2" e2="DDI-PubMed.17578901.s8.e3" /><pair ddi="false" e1="DDI-PubMed.17578901.s8.e2" e2="DDI-PubMed.17578901.s8.e4" /><pair ddi="false" e1="DDI-PubMed.17578901.s8.e3" e2="DDI-PubMed.17578901.s8.e3" /><pair ddi="false" e1="DDI-PubMed.17578901.s8.e3" e2="DDI-PubMed.17578901.s8.e4" /></sentence><sentence text=" Among ABC transporters, such as BCRP/ABCG2, multidrug resistance-associated protein (MRP) 2/ABCC2, and MRP4/ABCC4, which are candidates for the luminal efflux of methotrexate, ATP-dependent uptake of methotrexate by MRP4-expressing membrane vesicles was most potently inhibited by NSAIDs"><entity charOffset="163-175" id="DDI-PubMed.17578901.s9.e0" text="methotrexate" /><entity charOffset="201-213" id="DDI-PubMed.17578901.s9.e1" text="methotrexate" /><pair ddi="false" e1="DDI-PubMed.17578901.s9.e0" e2="DDI-PubMed.17578901.s9.e0" /><pair ddi="false" e1="DDI-PubMed.17578901.s9.e0" e2="DDI-PubMed.17578901.s9.e1" /></sentence><sentence text=" Salicylate and indomethacin were predicted to inhibit MRP4 at clinical plasma concentrations"><entity charOffset="1-11" id="DDI-PubMed.17578901.s10.e0" text="Salicylate" /><entity charOffset="16-28" id="DDI-PubMed.17578901.s10.e1" text="indomethacin" /><pair ddi="false" e1="DDI-PubMed.17578901.s10.e0" e2="DDI-PubMed.17578901.s10.e0" /><pair ddi="false" e1="DDI-PubMed.17578901.s10.e0" e2="DDI-PubMed.17578901.s10.e1" /></sentence><sentence text=" Diclofenac-glucuronide significantly inhibited MRP2-mediated transport of methotrexate in a concentration-dependent manner, whereas naproxen-glucuronide had no effect"><entity charOffset="1-23" id="DDI-PubMed.17578901.s11.e0" text="Diclofenac-glucuronide" /><entity charOffset="75-87" id="DDI-PubMed.17578901.s11.e1" text="methotrexate" /><entity charOffset="133-141" id="DDI-PubMed.17578901.s11.e2" text="naproxen" /><entity charOffset="142-153" id="DDI-PubMed.17578901.s11.e3" text="glucuronide" /><pair ddi="false" e1="DDI-PubMed.17578901.s11.e0" e2="DDI-PubMed.17578901.s11.e0" /><pair ddi="false" e1="DDI-PubMed.17578901.s11.e0" e2="DDI-PubMed.17578901.s11.e1" /><pair ddi="false" e1="DDI-PubMed.17578901.s11.e0" e2="DDI-PubMed.17578901.s11.e2" /><pair ddi="false" e1="DDI-PubMed.17578901.s11.e0" e2="DDI-PubMed.17578901.s11.e3" /><pair ddi="false" e1="DDI-PubMed.17578901.s11.e1" e2="DDI-PubMed.17578901.s11.e1" /><pair ddi="false" e1="DDI-PubMed.17578901.s11.e1" e2="DDI-PubMed.17578901.s11.e2" /><pair ddi="false" e1="DDI-PubMed.17578901.s11.e1" e2="DDI-PubMed.17578901.s11.e3" /><pair ddi="false" e1="DDI-PubMed.17578901.s11.e2" e2="DDI-PubMed.17578901.s11.e2" /><pair ddi="false" e1="DDI-PubMed.17578901.s11.e2" e2="DDI-PubMed.17578901.s11.e3" /></sentence><sentence text=" Inhibition of renal uptake (via OAT3) and efflux processes (via MRP2 and MRP4) explains the possible sites of drug-drug interaction for methotrexate with probenecid and some NSAIDs, including their glucuronides"><entity charOffset="137-149" id="DDI-PubMed.17578901.s12.e0" text="methotrexate" /><entity charOffset="155-165" id="DDI-PubMed.17578901.s12.e1" text="probenecid" /><entity charOffset="199-211" id="DDI-PubMed.17578901.s12.e2" text="glucuronides" /><pair ddi="false" e1="DDI-PubMed.17578901.s12.e0" e2="DDI-PubMed.17578901.s12.e0" /><pair ddi="false" e1="DDI-PubMed.17578901.s12.e0" e2="DDI-PubMed.17578901.s12.e1" /><pair ddi="false" e1="DDI-PubMed.17578901.s12.e0" e2="DDI-PubMed.17578901.s12.e2" /><pair ddi="false" e1="DDI-PubMed.17578901.s12.e1" e2="DDI-PubMed.17578901.s12.e1" /><pair ddi="false" e1="DDI-PubMed.17578901.s12.e1" e2="DDI-PubMed.17578901.s12.e2" /></sentence><sentence text="" /></document>